thealthЗдравоохранение ТаджикистанаHealth care of Tajikistan0514-2415Редакция журнала «Здравоохранение Таджикистана»10.52888/0514-2515-2024-360-1-95-101thealth-539Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWРецидивы туберкулёзаRecurrence of tuberculosisУкуматшоеваЛ. Ш.UkumatshoevaL. Sh.

Укуматшоева Лалъбегим Шозодаевна – старший преподаватель кафедры фтизиопульмонологии,

Душанбе.

Ukumatshoeva Lalbegim Shozodaevna – Senior Lecturer,

Dushanbe.

yasminjon@mail.ruБобоходжаевО. И.BobokhojaevO. I.

Душанбе.

Dushanbe.

ГОУ «Таджикский государственный медицинский университет им. Абуали ибни Сино», Кафедра фтизиопульмонологииТаджикистанSEI “Avicenna Tajik State Medical University”, Department of PhthisiopulmonologyTajikistan2024170520240195101Copyright © Укуматшоева Л.Ш., Бобоходжаев О.И., 20242024Укуматшоева Л.Ш., Бобоходжаев О.И.Ukumatshoeva L.S., Bobokhojaev O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zdrav.tj/jour/article/view/539

Обзор литературы, проведенный на основе доступной нам литературы, свидетельствует о том, что проблема реактивации туберкулёзного процесса после перенесенного туберкулёза лёгких является актуальной. Имеются определённые сложности в проведении дифференциальной диагностики между истинным рецидивом болезни и реинфекцией. Частота возникновения реактивации туберкулёза в разных странах значительно варьирует. В публикациях нет свидетельств о современном комплексном подходе к профилактике развития рецидивов туберкулёза лёгких. Пандемия COVID-19 также повысила риск увеличения развития реактиваций туберкулезного процесса. Назрела также необходимость внести изменения в порядок диспансерного наблюдения за больными, перенесшими ТБ, что несомненно, отразится на частоте развития рецидивов туберкулёзного процесса.

The problem of tuberculosis reactivation after pulmonary tuberculosis is urgent, according to a review of the available literature. There are certain difficulties in the differential diagnosis between a true relapse and a re-infection. The incidence of tuberculosis reactivation varies considerably from country to country. There is no evidence in the literature of a modern, integrated approach to preventing pulmonary tuberculosis relapse. The COVID-19 pandemic has also increased the risk of TB reactivation. There is also a need to make changes in the order of hospital observation of TB patients, which will undoubtedly affect the frequency of tuberculosis relapses.

туберкулёзрецидивычастотапричиныпрофилактические мерыtuberculosisrelapsesfrequencycausespreventive measuresReferencesАбильбаева А.А. Факторы, ассоциированные с развитием рецидива туберкулеза / А.А. Абильбаева, А.С. Тарабаева, И.М. Охас, Д.К. Куашова, И.М. Хаертынова, Э.А. Шуралев // Туберкулёз и болезни лёгких. - 2022. – Т.100, №10. - С. 30-36.Abilbaeva A.A. Faktory, assotsiirovannye s razvitiem retsidiva tuberkuleza [Factors associated with the development of tuberculosis relapse]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2022, Vol. 100, No. 10, pp. 30-36.Алексеенко С.Н. Ранние рецидивы туберкулеза легких – эпидемиологические и экономические проблемы / С.Н. Алексеенко, Н.Н. Дробот // Современные проблемы науки и образования. - 2019. – №2.Alekseenko S.N. Rannie retsidivy tuberkuleza legkikh – epidemiologicheskie i ekonomicheskie problemy [Early relapses of pulmonary tuberculosis - epidemiologic and economic challenges]. Sovremennye problemy nauki i obrazovaniya – Modern problems of science and education, 2019, No. 2.Алиев С.П. Эффективность выявления случаев туберкулёза среди населения г. Душанбе Республики Таджикистан / С.П. Алиев, О.И. Бобоходжаев, И.С. Махмудзода, Ф.О. Мирзоева, Л.Ш. Укуматшоева // Вестник Авиценны. - 2018. – Т.21, №4. - С. 56-61.Aliev S.P. Effektivnost vyyavleniya sluchaev tuberkulyoza sredi naseleniya g. Dushanbe Respubliki Tadzhikistan [Efficiency of tuberculosis case detection among the population of Dushanbe city of the Republic of Tajikistan]. Vestnik Avitsenny – Bulletin of Avicenna, 2018, Vol. 21, No. 4, pp. 56-61.Аллилуев А.С. Машинное обучение в прогнозировании рецидивов у больных туберкулезом с множественной лекарственной устойчивостью / А.С. Аллилуев, О.В. Филинюк, Е.Е. Шнайдер, С.В. Аксенов // Туберкулез и болезни легких. - 2021. - №99(11). - С. 27-34.Alliluev A.S. Mashinnoe obuchenie v prognozirovanii retsidivov u bolnykh tuberkulezom s mnozhestvennoy lekarstvennoy ustoychivostyu [Machine learning in predicting relapse in multidrug-resistant tuberculosis patients]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2021, No. 99 (11), pp. 27-34.Бобоходжаев О.И. К вопросу о реактивации туберкулёзного процесса / Бобоходжаев, О.И., У.Ю. Сироджидинова, Р.Р. Джумаев, И.С. Махмудзода // Вестник Авиценны. - 2018. – Т.20, №2-3. - С. 320-324.Bobokhodzhaev O.I. K voprosu o reaktivatsii tuberkulyoznogo protsessa [To the question of reactivation of tuberculosis process]. Vestnik Avitsenny – Bulletin of Avicenna, 2018, Vol. 20, No. 2-3, pp. 320-324.Гусейналиев Н.В. Совершенствование выявления туберкулеза в учреждениях первичного медицинского звена и его влияние на показатель заболеваемости // Туберкулез и болезни легких. - 2020. – №98 (10). - С. 41-46.Guseynaliev N.V. Sovershenstvovanie vyyavleniya tuberkuleza v uchrezhdeniyakh pervichnogo meditsinskogo zvena i ego vliyanie na pokazatel zabolevaemosti [Improvement of tuberculosis detection in primary health care facilities and its impact on morbidity rate]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 41-46.Зоркальцева Е.Ю. Клинические проявления рецидивов туберкулеза у больных ВИЧ-инфекцией / Е.Ю. Зоркальцева, Ю.О. Егорова // Туберкулез и болезни легких. - 2020. - №98 (6). - С. 32-35.Zorkaltseva E.Yu. Klinicheskie proyavleniya retsidivov tuberkuleza u bolnykh VICH-infektsiey [Clinical manifestations of tuberculosis relapses in HIV-infected patients]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (6), pp. 32-35.Корж Е.В. Эффективность лечения и рецидивы туберкулеза у больных ВИЧ-инфекцией с глубокой иммуносупрессией, начавших антиретровирусную терапию / Е.В. Корж, Н.А. Подчос, Л.В. Стрига, Т.С. Извекова, Н.А. Малявко // Туберкулез и болезни легких. - 2020. - №98 (10). - С. 11-18.Korzh E.V. Effektivnost lecheniya i retsidivy tuberkuleza u bolnykh VICh-infektsiey s glubokoy immunosupressiey, nachavshikh antiretrovirusnuyu terapiyu [Treatment efficacy and tuberculosis recurrence in profoundly immunosuppressed HIV-infected patients started on antiretroviral therapy]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 11-18.Кульчавеня Е.В. Рецидивы урогенитального туберкулеза / Е.В. Кульчавеня, С.Ю. Шевченко, Д.П. Холтобин, А.А. Баранчукова // Туберкулез и болезни легких. - 2020. - №98 (10). -С. 19-22.Kulchavenya E.V. Retsidivy urogenitalnogo tuberkuleza [Recurrences of urogenital tuberculosis]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (10), pp. 19-22.Нечаева О.Б. Состояние и перспективы противотуберкулезной службы России в период COVID-19 // Туберкулез и болезни легких. - 2020. - №98 (12). - С. 7-19.Nechaeva O.B. Sostoyanie i perspektivy protivotuberkuleznoy sluzhby Rossii v period COVID-19 [Status and prospects of the Russian TB service in the period of COVID-19]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2020, No. 98 (12), pp. 7-19.Cтерликов С.А. Влияние активного выявления случаев туберкулеза на результаты лечения взрослых пациентов с туберкулезом легких / С.А. Cтерликов, В.Б. Галкин, Б.М. Малиев, А.А. Широкова, В.А. Хоротэтто, А.С. Майжегишева // Туберкулез и болезни легких. - 2021. - №99 (7). - С. 33-40.Cterlikov S.A. Vliyanie aktivnogo vyyavleniya sluchaev tuberkuleza na rezultaty lecheniya vzroslykh patsientov s tuberkulezom legkikh [Impact of active TB case detection on treatment outcomes of adult patients with pulmonary tuberculosis]. Tuberkulyoz i bolezni lyogkikh - Tuberculosis and lung diseases, 2021, No. 99 (7), pp. 33-40.Cardona P. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. PLoS One, 2018, No. 13 (7), pp. e0200150.Cardona P. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. PLoS One, 2018, No. 13 (7), pp. e0200150.Chen Q. Recurrence Is a Noticeable Cause of Rifampicin-Resistant Mycobacterium tuberculosis in the Elderly Population in Jiangxi, China. Frontiers in Public Health, 2019, No. 7, pp. 182.Chen Q. Recurrence Is a Noticeable Cause of Rifampicin-Resistant Mycobacterium tuberculosis in the Elderly Population in Jiangxi, China. Frontiers in Public Health, 2019, No. 7, pp. 182.Crisan-Dabija R. Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes. Canadian Respiratory Journal, 2020, pp. 1401053.Crisan-Dabija R. Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes. Canadian Respiratory Journal, 2020, pp. 1401053.Cudahy P.G.T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20, pp. 789.Cudahy P.G.T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20, pp. 789.Dedefo M.G. Treatment Outcomes of Tuberculosis Retreatment Case and Its Determinants in West Ethiopia. The Open Respiratory Medicine Journal, 2019, No. 13, pp. 58–64.Dedefo M.G. Treatment Outcomes of Tuberculosis Retreatment Case and Its Determinants in West Ethiopia. The Open Respiratory Medicine Journal, 2019, No. 13, pp. 58–64.Folkvardsen D.B. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20 (1), pp. 789.Folkvardsen D.B. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, No. 20 (1), pp. 789.Folkvardsen D.B. Recurrent tuberculosis in patients infected with the predominant Mycobacterium tuberculosis outbreak strain in Denmark. New insights gained through whole genome sequencing. Infection, Genetics and Evolution, 2020, No. 80, pp. 104169.Folkvardsen D.B. Recurrent tuberculosis in patients infected with the predominant Mycobacterium tuberculosis outbreak strain in Denmark. New insights gained through whole genome sequencing. Infection, Genetics and Evolution, 2020, No. 80, pp. 104169.Furtado I. Getting back on the road towards tuberculosis elimination: lessons learnt from the COVID-19 pandemic. The Brazilian Journal of Pulmonology and international databases, 2021, No. 47 (2), pp. e20210123.Furtado I. Getting back on the road towards tuberculosis elimination: lessons learnt from the COVID-19 pandemic. The Brazilian Journal of Pulmonology and international databases, 2021, No. 47 (2), pp. e20210123.Maghradze N. Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing. PLoS One, 2019, No. 14 (10), pp. e0223610.Maghradze N. Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing. PLoS One, 2019, No. 14 (10), pp. e0223610.Mirsaeidi M. Patients at high risk of tuberculosis recurrence. International Journal of Mycobacteriology, 2018, No. 7, pp. 1-6.Mirsaeidi M. Patients at high risk of tuberculosis recurrence. International Journal of Mycobacteriology, 2018, No. 7, pp. 1-6.Reid M.J.A. Building a tuberculosis-free world while responding to the COVID-19 pandemic. Lancet, 2020, No. 396 (10259), pp. 1312-1313.Reid M.J.A. Building a tuberculosis-free world while responding to the COVID-19 pandemic. Lancet, 2020, No. 396 (10259), pp. 1312-1313.Sahu S. Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets. International Journal of Infectious Diseases, 2021, No. 113 (1), pp. S100-S103.Sahu S. Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets. International Journal of Infectious Diseases, 2021, No. 113 (1), pp. S100-S103.Shao Y. Relapse or Re-Infection, the Situation of Recurrent Tuberculosis in Eastern China. Frontiers in Cellular and Infection Microbiology, 2021, No. 11, pp. 638990.Shao Y. Relapse or Re-Infection, the Situation of Recurrent Tuberculosis in Eastern China. Frontiers in Cellular and Infection Microbiology, 2021, No. 11, pp. 638990.WHO Global tuberculosis report 2022. Geneva, World Health Organization Publ., 2022.WHO Global tuberculosis report 2022. Geneva, World Health Organization Publ., 2022.WHO Information Note. COVID-19: considerations for tuberculosis care. Geneva, 2021. 15 p.WHO Information Note. COVID-19: considerations for tuberculosis care. Geneva, 2021. 15 p.Wingfield T. Surveillance of tuberculosis cases attributable to relapse or reinfection in London, 2002-2015. PLoS One, 2019, No. 14 (2), pp. e0211972.Wingfield T. Surveillance of tuberculosis cases attributable to relapse or reinfection in London, 2002-2015. PLoS One, 2019, No. 14 (2), pp. e0211972.Xie Z. Factors associated with diagnostic delay in recurrent TB. BMC Public Health, 2020, No. 20 (1), pp. 1207.Xie Z. Factors associated with diagnostic delay in recurrent TB. BMC Public Health, 2020, No. 20 (1), pp. 1207.Zong Z. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Frontiers in Microbiology, 2018, No. 9, pp. 1858.Zong Z. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Frontiers in Microbiology, 2018, No. 9, pp. 1858.

The authors declare that there are no conflicts of interest present.